- Home
- REX vs COLL Comparison
REX vs COLL Comparison
Compare REX & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REX | COLL |
|---|---|---|
| Founded | 1980 | 2002 |
| Country | United States | United States |
| Employees | N/A | 423 |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 1994 | 2015 |
Fundamental Metrics
Financial Performance| Metric | REX | COLL |
|---|---|---|
| Price | $49.38 | $33.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $51.40 |
| AVG Volume (30 Days) | 120.6K | ★ 399.7K |
| Earning Date | 05-27-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.50 | 0.40 |
| Revenue | $650,487,000.00 | ★ $780,567,000.00 |
| Revenue This Year | $19.45 | $8.01 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $20.02 | $84.30 |
| Revenue Growth | 1.24 | ★ 23.62 |
| 52 Week Low | $30.02 | $28.34 |
| 52 Week High | $64.95 | $50.79 |
Technical Indicators
Market Signals| Indicator | REX | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 59.02 | 42.93 |
| Support Level | $31.24 | $31.56 |
| Resistance Level | $53.36 | $36.22 |
| Average True Range (ATR) | 1.71 | 1.69 |
| MACD | -0.18 | -0.17 |
| Stochastic Oscillator | 37.12 | 3.31 |
Price Performance
Historical ComparisonAbout REX REX American Resources Corporation
REX American Resources Corp operates as a holding company, which engages in investment in alternative energy and ethanol production entities. Its operating segments include Ethanol and By-Products. Its products include dried distillers grains, modified distillers grains, and non-food grade corn oil.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.